Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
388
datasets available to search
ShareScore release 0.7.1
Dataset results
388 results for “alcoholic fatty liver disease”
Figure S1. Mediation analysis on the effect of insulin resistance on intraocular pressure. Figure S2. Forest plot showing the OR (95% CI) for EIOP of ALD versus NAFLD and the OR (95% CI) for EIOP of drinkers versus non-drinkers. Abbreviations: OR, odds ratio; CI, confidence interval; ALD, alcoholic liver disease; NAFLD, non-alcoholic fatty liver disease.
<p>Figure S1. Mediation analysis on the effect of insulin resistance on intraocular pressure.</p> <p>Figure S2. Forest plot showing the OR (95% CI) for EIOP of ALD versus NAFLD and the OR (95% CI) for EIOP of drinkers versus non-drinkers. Abbreviations: OR, odds ratio; CI, confidence interval; ALD, alcoholic liver disease; NAFLD, non-alcoholic fatty liver disease.</p>
VISION Invited lecture - Bariatric surgery and non-alcoholic fatty liver disease
<p>Recording and presentation of the invited lecture that took place online on 16 June 2021 - <strong>Pantelis Antonakis, MD, PhD - Bariatric surgery and non-alcoholic fatty liver disease.</strong></p> <p>Bariatric surgery is a documented solution for morbid obesity. Additionally to excess weight loss, significant improvement in comorbidities is an established benefit after bariatric operations. In recent years, non-alcoholic fatty liver disease (NAFLD) has emerged as one of these comorbidities. Herein we will review the data supporting the positive effect of bariatric surgery in patients with NAFLD.</p>
Dihydrosphingolipids are associated with steatosis and increased fibrosis damage in human and animal models of non-alcoholic fatty liver disease
<p>Data sets used for the article entitled: "Accumulation of dihydrosphingolipids and neutral lipids is related to steatosis and fibrosis damage in human and animal models of non-alcoholic fatty liver disease"</p> <p>- Patient data: DATA Patients JLR.xlsx</p> <p>- Mouse data: DATA Mice.xlsx</p>
Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER St
ClinicalTrials.gov study NCT04216589. IPD Sharing: YES. Countries: 2. Publications: 2.
Study of Various Treatments in Non-alcoholic Fatty Liver Disease (NAFLD) Patients Who Have Aspects of Non-alcoholic Steatohepatitis (NASH)
ClinicalTrials.gov study NCT04147195. IPD Sharing: YES. Countries: 3. Publications: 1.
Raw data related to: Randomised Clinical Trial: Calorie Restriction Regimen with Tomato Juice Supplementation Ameliorates Oxidative Stress and Preserves a Proper Immune Surveillance Modulating Mitochondrial Bioenergetics of T-Lymphocytes in Obese Children Affected by Non-Alcoholic Fatty Liver Disease (NAFLD)
<p><strong>Abstract</strong></p> <p>Fatty liver disease is a serious complication of childhood obesity. Calorie-restricted regimen (RCR) is one of the e ective therapy for this condition. Aim of the study was to evaluate the effect of lycopene-rich tomato sauce with oregano and basil extracts in obese children with fatty liver on RCR. 61 obese children with fatty liver were enrolled, 52 completed the study. A randomized cross over clinical trial was performed. Participants were assigned to RCR alone or with a supplement of lycopene-rich tomato juice for 60 days; subsequently, the groups were switched to the alternative regimen for the next 60 days. Reduction in BMI, HOMA-IR, cholesterol, triglycerides, liver size, and steatosis was more profound in tomato-supplemented group. Leptin decreased in both groups whereas adiponectin raised only after tomato supplementation. RCR is associated with the impaired engagement of T-cells glycolysis and proliferation, tomato-supplementation resulted in glycolytic metabolic activation of T-cells. Tomato juice ameliorates glucose and lipid metabolism in obese children, improve oxidative and inflammatory state and modulates the mitochondrial metabolism of T-cells contributing to a maintenance of a proper immune surveillance in children, impaired by RCR. The addition of tomato to RCR could be considered a protective and preventive support to obese child.</p> <p><strong>Progetto giovani ricercatori </strong>[GR-2016-02363725] dal titolo: "Immune Tolerance, Metabolism and Multiple Sclerosis: Novel Molecular Tools to Monitor Disease Pathogenesis and Progression"</p>
Association of fat-to-muscle ratio with non-alcoholic fatty liver disease: a single-centre retrospective study
<p><strong>Objectives</strong>: Sarcopenia is a known risk factor for non-alcoholic fatty liver disease (NAFLD). Studies evaluating the association between the fat-to-muscle ratio (FMR) and NAFLD are limited. Therefore, the aim of our study was to investigate the association between FMR and NAFLD.</p> <p><strong>Design:</strong> A retrospective study was conducted on the individuals who underwent health examination in Wuhan Union Hospital between January 2020 and November 2021. Clinical data were collected from electronic medical records.</p> <p><strong>Setting:</strong> Our study was conducted in a hospital in China.</p> <p><strong>Participants:</strong> A total of 1,592 participants aged ≥40 years who underwent body composition analysis and liver ultrasonography were retrospectively reviewed.</p> <p><strong>Primary outcome measures:</strong> Liver ultrasonography was used to assess liver steatosis, and the Fibrosis-4 Index (FIB-4) was used to calculate the risk scores for liver fibrosis. The 10-year atherosclerotic cardiovascular disease (ASCVD) risk prediction model was used to calculate ASCVD risk scores.</p> <p><strong>Results:</strong> The FMR was significantly higher in individuals with NAFLD than in those without NAFLD (P<0.001). The prevalence of NAFLD gradually increased from FMR tertile 1 (reference) to tertile 2 (OR=1.49, 95% CI: 1.13–1.97) and tertile 3 (OR=2.85, 95% CI: 2.08–3.90). In addition, patients with NAFLD in FMR tertile 3 had a significantly higher risk of liver fibrosis (OR=4.48, 95% CI: 2.12–9.50) and ASCVD (OR=4.63, 95% CI: 2.62–8.19) than those in FMR tertile 1 after adjustment for multiple confounders.</p> <p><strong>Conclusion:</strong> In this study, we found a significant association between FMR and NAFLD. A higher FMR indicates a higher risk of NAFLD in the study population and a higher risk of liver fibrosis and ASCVD in NAFLD patients.</p>
Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment
ClinicalTrials.gov study NCT01002547. IPD Sharing: NO. Countries: 1. Publications: 1.
Insulin Resistance in Non-alcoholic Fatty Liver Disease
ClinicalTrials.gov study NCT00252499. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Non-Alcoholic Fatty Liver Disease in a Saudi Cohort With Type 2 Diabetes Mellitus
ClinicalTrials.gov study NCT05697991. IPD Sharing: NO. Countries: 1. Publications: 1.
The Impact of Different Exercise Modes on Bile Acid Levels and Liver Function in Patients With Non-alcoholic Fatty Liver Disease
ClinicalTrials.gov study NCT06338449. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Impact of Lifestyle Interventions on Cognitive Decline in Non-alcoholic Fatty Liver Disease
ClinicalTrials.gov study NCT07294963. IPD Sharing: YES. Countries: 1. Publications: 4.
Insulin Resistance in Non-alcoholic Fatty Liver Disease
ClinicalTrials.gov study NCT01289639. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Fetuin-A, a Promising Serum Biomarker for Diagnosis of Non-Alcoholic Fatty Liver Disease
ClinicalTrials.gov study NCT06097039. IPD Sharing: NO. Countries: 1. Publications: 6.
The Effect Of NS-0200 Versus Placebo On Hepatic Fat Content In Patients With Non Alcoholic Fatty Liver Disease
ClinicalTrials.gov study NCT02546609. IPD Sharing: NO. Countries: 1. Publications: 2.
A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.
ClinicalTrials.gov study NCT03776175. IPD Sharing: YES. Countries: 1. Publications: 1.
Study of the Safety and Tolerability of AXA1125 and AXA1957 in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)
ClinicalTrials.gov study NCT04073368. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Sitagliptin Versus Placebo in the Treatment of Non-alcoholic Fatty Liver Disease
ClinicalTrials.gov study NCT01963845. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Fucoidan Improves the Metabolic Profiles of Patients With Non-alcoholic Fatty Liver Disease (NAFLD)
ClinicalTrials.gov study NCT02875392. IPD Sharing: NO. Countries: 1. Publications: 1.
Efficacy of a Natural Components Mixture in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)
ClinicalTrials.gov study NCT02369536. IPD Sharing: NO. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.